Metabonomic Profiling of Bladder Cancer

• Published in: Journal of proteome research Vol. 14; no. 2; pp. 587 - 602
• Main Authors: Chan, Eric Chun Yong, Pasikanti, Kishore Kumar, Hong, Yanjun, Ho, Paul C, Mahendran, Ratha, Raman Nee Mani, Lata, Chiong, Edmund, Esuvaranathan, Kesavan
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 06.02.2015
• Subjects: biochemical pathways; biomarkers; clinical trials; cystoscopy; early diagnosis; Humans; metabolites; Metabolomics; monitoring; patients; urinary bladder neoplasms; Urinary Bladder Neoplasms - metabolism; Urinary Bladder Neoplasms - pathology; metabonomics; NMR; GC−MS; biomarker; LC−MS; bladder cancer
• ISSN: 1535-3893; 1535-3907; 1535-3907
• DOI: 10.1021/pr500966h

Early diagnosis and life-long surveillance are clinically important to improve the long-term survival of bladder cancer patients. Currently, a noninvasive biomarker that is as sensitive and specific as cystoscopy in detecting bladder tumors is lacking. Metabonomics is a complementary approach for identifying perturbed metabolic pathways in bladder cancer. Significant progress has been made using modern metabonomic techniques to characterize and distinguish bladder cancer patients from control subjects, identify marker metabolites, and shed insights on the disease biology and potential therapeutic targets. With its rapid development, metabonomics has the potential to impact the clinical management of bladder cancer patients in the future by revolutionizing the diagnosis and life-long surveillance strategies and stratifying patients for diagnostic, surgical, and therapeutic clinical trials. An introduction to metabonomics, typical metabonomic workflow, and critical evaluation of metabonomic investigations in identifying biomarkers for the diagnosis of bladder cancer are presented.